CStone Pharmaceuticals (2616.HK)

HKD 2.39

(-6.64%)

Operating Income Summary of CStone Pharmaceuticals

CStone Pharmaceuticals's latest annual operating income in 2023 was -534.6 Million CNY , up 35.77% from previous year.
CStone Pharmaceuticals's latest quarterly operating income in 2024 Q1 was -1.83 Million CNY , up 98.96% from previous quarter.
CStone Pharmaceuticals reported an annual operating income of -832.27 Million CNY in 2022, up 55.08% from previous year.
CStone Pharmaceuticals reported an annual operating income of -1.85 Billion CNY in 2021, down -51.6% from previous year.
CStone Pharmaceuticals reported a quarterly operating income of -1.83 Million CNY for 2024 Q1, up 98.96% from previous quarter.
CStone Pharmaceuticals reported a quarterly operating income of -534.6 Million CNY for 2023 FY, up 35.77% from previous quarter.

Annual Operating Income Chart of CStone Pharmaceuticals (2023 - 2016)

Historical Annual Operating Income of CStone Pharmaceuticals (2023 - 2016)

Year	Operating Income	Operating Income Growth
2023	-534.6 Million CNY	35.77%
2022	-832.27 Million CNY	55.08%
2021	-1.85 Billion CNY	-51.6%
2020	-1.22 Billion CNY	21.66%
2019	-1.56 Billion CNY	-47.3%
2018	-1.05 Billion CNY	-336.78%
2017	-242.47 Million CNY	7.51%
2016	-262.17 Million CNY	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	-1.83 Million CNY	0.0%
2024 Q1	-1.83 Million CNY	98.96%
2023 FY	-534.6 Million CNY	35.77%
2023 Q1	-126.98 Million CNY	52.39%
2023 Q3	-175.8 Million CNY	-38.44%
2023 Q2	-126.98 Million CNY	0.0%
2023 Q4	-175.8 Million CNY	0.0%
2022 Q4	-266.69 Million CNY	0.0%
2022 FY	-832.27 Million CNY	55.08%
2022 Q3	-266.69 Million CNY	-40.83%
2022 Q2	-189.37 Million CNY	0.0%
2022 Q1	-189.37 Million CNY	64.84%
2021 Q4	-538.61 Million CNY	0.0%
2021 Q3	-538.61 Million CNY	-43.21%
2021 FY	-1.85 Billion CNY	-51.6%
2021 Q1	-376.1 Million CNY	-109.83%
2021 Q2	-376.1 Million CNY	0.0%
2020 Q2	-366.71 Million CNY	0.0%
2020 Q3	-179.24 Million CNY	51.12%
2020 FY	-1.22 Billion CNY	21.66%
2020 Q4	-179.24 Million CNY	0.0%
2020 Q1	-366.71 Million CNY	38.23%
2019 Q3	-593.72 Million CNY	-116.03%
2019 FY	-1.56 Billion CNY	-47.3%
2019 Q4	-593.72 Million CNY	0.0%
2019 Q1	-274.83 Million CNY	52.45%
2019 Q2	-274.83 Million CNY	0.0%
2018 Q1	-271.64 Million CNY	-389.51%
2018 FY	-1.05 Billion CNY	-336.78%
2018 Q4	-577.94 Million CNY	-535.6%
2018 Q3	132.67 Million CNY	148.84%
2018 Q2	-271.64 Million CNY	0.0%
2017 FY	-242.47 Million CNY	7.51%
2017 Q4	-55.49 Million CNY	0.0%
2016 FY	-262.17 Million CNY	0.0%

Peer Operating Income Comparison of CStone Pharmaceuticals

Name	Operating Income	Operating Income Difference
Uni-Bio Science Group Limited	67.76 Million HKD	888.878%
CK Life Sciences Int'l., (Holdings) Inc.	897.95 Million HKD	159.536%